Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 125

1.

Immune landscape and in vivo immunogenicity of NY-ESO-1 tumor antigen in advanced neuroblastoma patients.

Camisaschi C, Renne SL, Beretta V, Rini F, Spagnuolo RD, Tuccitto A, Podda MG, Parmiani G, Rivoltini L, Collini P, Castelli C, Luksch R.

BMC Cancer. 2018 Oct 16;18(1):983. doi: 10.1186/s12885-018-4910-8.

2.

Soluble NKG2D ligands are biomarkers associated with the clinical outcome to immune checkpoint blockade therapy of metastatic melanoma patients.

Maccalli C, Giannarelli D, Chiarucci C, Cutaia O, Giacobini G, Hendrickx W, Amato G, Annesi D, Bedognetti D, Altomonte M, Danielli R, Calabrò L, Di Giacomo AM, Marincola FM, Parmiani G, Maio M.

Oncoimmunology. 2017 May 8;6(7):e1323618. doi: 10.1080/2162402X.2017.1323618. eCollection 2017.

3.

Immunomodulating and Immunoresistance Properties of Cancer-Initiating Cells: Implications for the Clinical Success of Immunotherapy.

Maccalli C, Parmiani G, Ferrone S.

Immunol Invest. 2017 Apr;46(3):221-238. doi: 10.1080/08820139.2017.1280051. Epub 2017 Mar 13. Review.

PMID:
28287848
4.

"Cancer Bio-Immunotherapy in Siena": Thirteenth Meeting of the Network Italiano per la Bioterapia dei Tumori (NIBIT), Siena, Italy, October 8-10, 2015.

Maio M, Bertocci E, Fazio C, Chiarucci C, Cutaia O, Scala E, Giacobini G, Lofiego MF, Fonsatti E, Maccalli C, Nicolay HJ, Parmiani G; NIBIT.

Cancer Immunol Immunother. 2016 Nov;65(11):1423-1431. Epub 2016 Sep 12. No abstract available.

PMID:
27619513
5.

Immunological markers and clinical outcome of advanced melanoma patients receiving ipilimumab plus fotemustine in the NIBIT-M1 study.

Maccalli C, Giannarelli D, Capocefalo F, Pilla L, Fonsatti E, Di Giacomo AM, Parmiani G, Maio M.

Oncoimmunology. 2015 Aug 12;5(2):e1071007. eCollection 2016 Feb.

6.

Melanoma Cancer Stem Cells: Markers and Functions.

Parmiani G.

Cancers (Basel). 2016 Mar 11;8(3). pii: E34. doi: 10.3390/cancers8030034. Review.

7.

T cell neoepitope discovery in colorectal cancer by high throughput profiling of somatic mutations in expressed genes.

Mennonna D, Maccalli C, Romano MC, Garavaglia C, Capocefalo F, Bordoni R, Severgnini M, De Bellis G, Sidney J, Sette A, Gori A, Longhi R, Braga M, Ghirardelli L, Baldari L, Orsenigo E, Albarello L, Zino E, Fleischhauer K, Mazzola G, Ferrero N, Amoroso A, Casorati G, Parmiani G, Dellabona P.

Gut. 2017 Mar;66(3):454-463. doi: 10.1136/gutjnl-2015-309453. Epub 2015 Dec 17.

8.

Future perspectives in melanoma research: meeting report from the "Melanoma Bridge": Napoli, December 3rd-6th 2014.

Ascierto PA, Atkins M, Bifulco C, Botti G, Cochran A, Davies M, Demaria S, Dummer R, Ferrone S, Formenti S, Gajewski TF, Garbe C, Khleif S, Kiessling R, Lo R, Lorigan P, Arthur GM, Masucci G, Melero I, Mihm M, Palmieri G, Parmiani G, Puzanov I, Romero P, Schilling B, Seliger B, Stroncek D, Taube J, Tomei S, Zarour HM, Testori A, Wang E, Galon J, Ciliberto G, Mozzillo N, Marincola FM, Thurin M.

J Transl Med. 2015 Nov 30;13:374. doi: 10.1186/s12967-015-0736-1.

9.

Integrating Immune Checkpoint Blockade with Anti-Neo/Mutated Antigens Reactivity to Increase the Clinical Outcome of Immunotherapy.

Parmiani G, Maccalli C, Maio M.

Vaccines (Basel). 2015 May 21;3(2):420-8. doi: 10.3390/vaccines3020420. Review.

10.

Consensus nomenclature for CD8+ T cell phenotypes in cancer.

Apetoh L, Smyth MJ, Drake CG, Abastado JP, Apte RN, Ayyoub M, Blay JY, Bonneville M, Butterfield LH, Caignard A, Castelli C, Cavallo F, Celis E, Chen L, Colombo MP, Comin-Anduix B, Coukos G, Dhodapkar MV, Dranoff G, Frazer IH, Fridman WH, Gabrilovich DI, Gilboa E, Gnjatic S, Jäger D, Kalinski P, Kaufman HL, Kiessling R, Kirkwood J, Knuth A, Liblau R, Lotze MT, Lugli E, Marincola F, Melero I, Melief CJ, Mempel TR, Mittendorf EA, Odun K, Overwijk WW, Palucka AK, Parmiani G, Ribas A, Romero P, Schreiber RD, Schuler G, Srivastava PK, Tartour E, Valmori D, van der Burg SH, van der Bruggen P, van den Eynde BJ, Wang E, Zou W, Whiteside TL, Speiser DE, Pardoll DM, Restifo NP, Anderson AC.

Oncoimmunology. 2015 Feb 25;4(4):e998538. eCollection 2015 Apr.

11.

Self-adjuvanted mRNA vaccination in advanced prostate cancer patients: a first-in-man phase I/IIa study.

Kübler H, Scheel B, Gnad-Vogt U, Miller K, Schultze-Seemann W, Vom Dorp F, Parmiani G, Hampel C, Wedel S, Trojan L, Jocham D, Maurer T, Rippin G, Fotin-Mleczek M, von der Mülbe F, Probst J, Hoerr I, Kallen KJ, Lander T, Stenzl A.

J Immunother Cancer. 2015 Jun 16;3:26. doi: 10.1186/s40425-015-0068-y. eCollection 2015.

12.

"Cancer Bio-Immunotherapy in Siena": Twelfth Meeting of the Network Italiano per la Bioterapia dei Tumori (NIBIT), Siena, Italy, October 9-11, 2014.

Maio M, Bertocci E, Pilla L, Fazio C, Chiarucci C, Cutaia O, Fonsatti E, Maccalli C, Parmiani G; NIBIT.

Cancer Immunol Immunother. 2016 Jan;65(1):119-26. doi: 10.1007/s00262-015-1699-z. Epub 2015 May 6. No abstract available.

PMID:
25944004
13.

A pilot Phase I study combining peptide-based vaccination and NGR-hTNF vessel targeting therapy in metastatic melanoma.

Parmiani G, Pilla L, Corti A, Doglioni C, Cimminiello C, Bellone M, Parolini D, Russo V, Capocefalo F, Maccalli C.

Oncoimmunology. 2014 Dec 21;3(11):e963406. eCollection 2014 Nov.

14.

Preliminary results of contrast-enhanced sonography in the evaluation of the response of uveal melanoma to gamma-knife radiosurgery.

Venturini M, Colantoni C, Modorati G, Di Nicola M, Colucci A, Agostini G, Picozzi P, De Cobelli F, Parmiani G, Mortini P, Bandello F, Del Maschio A.

J Clin Ultrasound. 2015 Sep;43(7):421-30. doi: 10.1002/jcu.22262. Epub 2015 Feb 20.

PMID:
25703863
15.

Peptide-based vaccines for cancer therapy.

Parmiani G, Russo V, Maccalli C, Parolini D, Rizzo N, Maio M.

Hum Vaccin Immunother. 2014;10(11):3175-8. doi: 10.4161/hv.29418. Review.

16.

Awareness and understanding of cancer immunotherapy in Europe.

Mellstedt H, Gaudernack G, Gerritsen WR, Huber C, Melero I, Parmiani G, Scholl S, Thatcher N, Wagstaff J, Zielinski C.

Hum Vaccin Immunother. 2014;10(7):1828-35. doi: 10.4161/hv.28943.

17.

Somatically mutated tumor antigens in the quest for a more efficacious patient-oriented immunotherapy of cancer.

Trajanoski Z, Maccalli C, Mennonna D, Casorati G, Parmiani G, Dellabona P.

Cancer Immunol Immunother. 2015 Jan;64(1):99-104. doi: 10.1007/s00262-014-1599-7. Epub 2014 Aug 28. Review.

PMID:
25164877
18.

Therapeutic vaccines for cancer: an overview of clinical trials.

Melero I, Gaudernack G, Gerritsen W, Huber C, Parmiani G, Scholl S, Thatcher N, Wagstaff J, Zielinski C, Faulkner I, Mellstedt H.

Nat Rev Clin Oncol. 2014 Sep;11(9):509-24. doi: 10.1038/nrclinonc.2014.111. Epub 2014 Jul 8. Review.

PMID:
25001465
19.

"Cancer Bio-Immunotherapy in Siena": Eleventh Meeting of the Network Italiano per la Bioterapia dei Tumori (NIBIT), Siena, Italy, October 17-19, 2013.

Maio M, Nicolay HJ, Cutaia O, Fonsatti E, Parmiani G.

Cancer Immunol Immunother. 2015 Jan;64(1):131-5. doi: 10.1007/s00262-014-1577-0. Epub 2014 Jul 4. No abstract available.

PMID:
24993565
20.

Efficacy and safety of ipilimumab in elderly patients with pretreated advanced melanoma treated at Italian centres through the expanded access programme.

Chiarion Sileni V, Pigozzo J, Ascierto PA, Grimaldi AM, Maio M, Di Guardo L, Marchetti P, de Rosa F, Nuzzo C, Testori A, Cocorocchio E, Bernengo MG, Guida M, Marconcini R, Merelli B, Parmiani G, Rinaldi G, Aglietta M, Grosso M, Queirolo P.

J Exp Clin Cancer Res. 2014 Apr 4;33:30. doi: 10.1186/1756-9966-33-30.

Supplemental Content

Loading ...
Support Center